Novel Oncolytic Virus Effective in Melanoma

Article

The novel immunotherapy talimogene laherparepvec has become the first oncolytic virus to successfully complete a phase III trial in advanced melanoma.

Systemic tumor-specific immune response elicited by an oncolytic immunotherapy.

The novel immunotherapy talimogene laherparepvec (TVEC) has become the first oncolytic virus to successfully complete a phase III trial in advanced melanoma, according to the drug’s developer, Amgen.

In the trial, TVEC, a genetically modified version of herpes simplex virus type 1, was compared to granulocyte-macrophage colony-stimulating factor (GM-CSF) as a treatment for patients with advanced melanoma. Overall, the study met its primary endpoint with a significant improvement in durable response rate (DRR) in the TVEC arm. The data showed an overall survival (OS) trend favoring TVEC.

Although not a standard treatment for melanoma, GM-CSF was used as the comparator in this trial due to TVEC’s mechanism of action. When injected into the tumor, TVEC is able to replicate until it causes tumor cell lysis. Upon lysis, the engineered virus expresses GM-CSF in the tumor tissue, with the goal of stimulating a systemic immune response and killing tumor cells throughout the body.

“These are the first phase III results of this novel approach to cancer therapy,” said Sean E. Harper, MD, executive vice president of Research and Development at Amgen, in a statement. “A high unmet need exists in melanoma and we believe the innovative mechanism of action of talimogene laherparepvec may offer a promising approach for these patients.”

In the phase III trial, 439 patients with unresected stage IIIB, IIIC, or IV melanoma were randomized 2:1 to receive either TVEC or subcutaneous GM-CSF. The primary endpoint, DRR, was defined as the rate of complete or partial response lasting for 6 or more months.

The DRR rate in the TVEC arm was 16% compared with 2% in the GM-CSF arm. Data for an analysis of the secondary endpoint of OS has not yet matured, but is trending in favor of TVEC. According to Amgen, mature OS data are expected to become available in late 2013.

The most common serious adverse events were disease progression, cellulitis, and pyrexia. Additional safety and efficacy data are expected to be presented at the 2013 ASCO Annual Meeting.

Related Videos
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Daniel Olson, MD
Omid Hamid, MD
Michael R. Migden, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Related Content
Eric S. Christenson, MD, assistant professor, oncology, Johns Hopkins Medicine

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024
Article
Jeffrey S. Weber, MD, PhD

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

November 6th 2023
Podcast
Ritu Salani, MD

Clinicians Turn Their Focus to pMMR Disease Following Immunotherapy’s Entrance Into dMMR Endometrial Cancer

April 16th 2024
Article
Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023
Podcast
Do-Youn Oh, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine

Durvalumab Plus Chemo Sustains 3-Year OS Benefit in Advanced Biliary Tract Cancer

April 16th 2024
Article
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center

Insider Insights: Unveiling Takeaways from AACR 2024

April 11th 2024
Article